StockNews.AI
INKT
StockNews.AI
106 days

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

1. MiNK Therapeutics to release Q1 2025 financial results on May 15. 2. Conference call scheduled for 8:30 a.m. ET to discuss results. 3. Company specializes in allogeneic iNKT therapies for cancer treatment. 4. Focus on scalable manufacturing for off-the-shelf cell therapies. 5. Potential market reaction anticipated from financial results and announcements.

Earnings
+1.29%Current Return
VS
-1.16%S&P 500
$7.286205/05 12:35 PM EDTEvent Start
$7.3805/06 07:09 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming Q1 results may show progress in clinical-stage pipeline; positive investor sentiment historically follows reports.

How important is it?

The earnings report may demonstrate progress, influencing investor confidence and stock movement.

Why Short Term?

The financial results announcement is imminent and likely to influence investor actions quickly.

Related Companies

XLRNBMYFATE
May 05, 2025 12:30 ET  | Source: MiNK Therapeutics NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 9822477 Webcast A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/jgzwe9ny/. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact 917-362-1370 investor@minktherapeutics.com   Media Contact 781-674-4428 communications@minktherapeutics.com   

Related News